A5072984329- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Esophageal Cancer Research and Treatment
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Histone Deacetylase Inhibitors Research
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Glycosylation and Glycoproteins Research
- Fibroblast Growth Factor Research
- Barrier Structure and Function Studies
- Cancer therapeutics and mechanisms
- Ferroptosis and cancer prognosis
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
Anhui Provincial Hospital
2022-2024
University of Science and Technology of China
2022-2023
Soochow University
2023
First Affiliated Hospital of Soochow University
2023
Anhui Medical University
2015-2022
First Affiliated Hospital of Anhui Medical University
2015
3037 Background: Prognosis for advanced pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC) remains poor, with limited treatment options available. Expression of claudin18.2 (CLDN18.2) has emerged as a potential target anti-cancer treatment. Herein, we report preliminary safety efficacy results IBI343, an antibody-drug conjugate (ADC) consisting anti-CLDN18.2 monoclonal antibody conjugated to exatecan (topoisomerase I inhibitor), in patients (pts) PDAC or BTC phase 1...
1102 Background: MRG002 is a novel HER2-targeted ADC, composed of sugar-modified trastuzumab, MMAE payload and cleavable vc-linker. was effective in HER2-low expressing breast cancer preclinical studies. Hence, we conducted the phase II study to evaluate safety anti-tumor efficacy HER-low cancer. Methods: HER2 low tumor expression determined by central lab had be immunohistochemistry (IHC)1+ or 2+/ISH-. Eligible patients advanced/metastatic that failed standard therapies. administered...
8505 Background: Monoclonal antibodies against programmed death-ligand 1 (PD-L1) have been approved for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy. However, whether a death (PD-1) inhibitor provides similar survival benefit this patient population remains unclear. In study, efficacy and safety serplulimab, novel humanized monoclonal anti-PD-1 antibody, were assessed chemotherapy previously untreated ES-SCLC patients. Methods:...
4011 Background: CLDN18.2 expression has been observed in various solid tumors. In pancreatic ductal adenocarcinoma (PDAC), positive was reported nearly 60% patients (pts), indicating its potential as a novel target for anti-tumor therapy. IBI389 is an anti-CLDN18.2/CD3 bispecific antibody that induces immune synapse formations by linking CD3 molecules T-cell receptor complexes and antigens on the membrane of tumor cells. Herein, we report preliminary result from phase I study to evaluate...
Abstract Background: The phase III ORIENT-16 trial evaluated sin (a PD-1 inhibitor) versus placebo plus chemo as first-line (1L) treatment in pts with advanced G/GEJ adenocarcinoma. Sin+chemo previously showed a significant improvement OS vs PD-L1 combined positive score (CPS) ≥5 (HR 0.660; 95% CI 0.505-0.864; P=0.0023) and all 0.766; 0.626-0.936; P=0.0090), median follow-up of 18.8 months (m) at interim analysis (Xu, et al. Ann Oncol 2021). Here we report the results from final...
2519 Background: CLDN18.2 expression has been observed in various solid tumors especially gastric cancer, indicating its potential as a novel target for anti-tumor therapy. IBI389 is an anti-CLDN18.2/CD3 bispecific antibody that induces immune synapse formations by linking CD3 molecules T-cell receptor complexes and antigens on the membrane of tumor cells. Herein, we report preliminary results from phase I study to evaluate safety efficacy patients (pts) with advanced tumors. Methods:...
Abstract HA121-28, a promising multikinase inhibitor, mainly targets rearranged during transfection (RET) fusions and selectively vascular endothelial growth factor receptor-2, receptor, fibroblast receptor 1-3. The safety, pharmacokinetics, efficacy of HA121-28 were assessed in advanced solid tumors (phase 1, ClinicalTrials.gov NCT03994484) RET fusion-positive non-small-cell lung cancer (RET-TKI naive NSCLC, phase 2, NCT05117658). was administered orally doses range from 25 to 800 mg under...
Abstract Background: There is controversy over whether Granulocyte colony-stimulating factor (G-CSF) can be used within 24 h after chemotherapy. Efbemalenograstim α a novel long-acting G-CSF approved by FDA in 2023. Guard-02 trial (ChiCTR2300078792) was to evaluate the efficacy and safety of efbemalenograstim for prevention chemotherapy-induced neutropenia (CIN) Methods: This prospective, multicenter, single-arm, two-stage clinical study. Breast cancer patients received chemotherapy with...
9001 Background: Patients (pts) with EGFRm + NSCLC have high rates of CNS metastasis, few treatment options, and a poor prognosis. So far there are no solid evidence from head to phase 3 trials in this setting. The potent EGFR TKI AZD3759 has blood–brain barrier penetration, preliminary data shown promising intracranial (IC) systemic antitumor activity, tolerable safety profile. Methods: This was the first 3, open-label, multicenter, randomized controlled trial compare efficacy first-line...
8533 Background: The combination of immune checkpoint inhibitors with chemotherapy has become the first-line treatment for advanced non-squamous NSCLC negative driver genes, but not gene-positive tumors. PM8002 is a bispecific antibody targeting both PD-L1 and VEGF-A. Previous published data indicated that tolerable safety profile potential anti-tumor activity in variety solid tumors (SITC2022 abstract #725 ASCO2023 #2536). Here, we report results patients an ongoing Phase Ib/IIa trial....
HLX04 is a proposed biosimilar of bevacizumab. This phase III study aimed to evaluate the efficacy, safety, and immunogenicity compared with reference bevacizumab in combination XELOX or mFOLFOX6 as first-line treatment for recurrent/metastatic colorectal cancer (CRC). In this double-blind, parallel-group study, patients were randomized 1:1 receive (7.5 mg/kg every 3 weeks when combined XELOX; 5 2 mFOLFOX6). The primary endpoint was progression-free survival rate at week 36 (PFSR36w) per...
The prognostic value of lysine-specific demethylase 1 (LSD1) overexpression in various cancers has been investigated by many studies with inconsistent results. A meta-analysis was performed to assess the association between LSD1 and overall survival (OS) cancer patients. Eligible were identified searching online databases PubMed China National Knowledge Infrastructure up February 2015. Hazard ratios (HRs) 95% confidence intervals (CIs) calculated clarify correlation expression prognosis...
391 Background: Claudin18.2 (CLDN18.2) is normally confined in tight junction of the gastric mucosa, but also often expressed several cancer types. AB011 a humanized, anti-CLDN18.2 monoclonal antibody (IgG1), which has shown impressive therapeutic synergy between and cytotoxic agents preclinical research. Here we report preliminary data on both as monotherapy combined with CAPOX patients advanced solid tumors (AB011-ST-01, NCT04400383). Methods: The primary objectives were to evaluate safety...
Chemotherapy-induced thrombocytopenia (CIT) increases the risk of bleeding, necessitates chemotherapy dose reductions and delays, negatively impacts prognosis.
Abstract Background: In patients (pts) with previously treated aHCC, pembro demonstrated comparable efficacy and safety vs placebo (pbo) in the phase 3 KEYNOTE-240 (NCT02702401) KEYNOTE-394 (NCT03062358) studies global Asian populations, respectively. The hazard ratio ([HR]; 95% confidence interval [CI]) for OS was 0.781 (0.611-0.998) 0.79 (0.63-0.99) KEYNOTE-394; HR (95% CI) PFS 0.78 (0.61-0.99) 0.74 (0.60-0.92), ORR differences pbo were similar (13.8% [95% CI, 7.7-19.5]) (11.4% 6.7-16.0])....
Abstract Background Entinostat is a novel, potent, once weekly, orally bioavailable, class I selective histone deacetylase (HDAC) inhibitor. In previous Phase II study, the combination of entinostat with exemestane showed significant improvement overall survival in patients advanced hormone receptor (HR) positive breast cancer. To verify and further confirm benefit HDAC inhibitor we designed randomized, controlled trial to assess efficacy safety larger population Chinese advanced, HR Methods...
Abstract Pemigatinib is a selective fibroblast growth factor receptor (FGFR)1–3 inhibitor and has demonstrated acceptable tolerability clinical activity in advanced solid tumors Western population. This phase I trial evaluated pharmacokinetics/pharmacodynamics (PK/PD) characteristics, preliminary safety efficacy of pemigatinib Chinese patients with advanced, tumors. Patients unresectable or metastatic bearing FGF/FGFR1-3 alterations received oral at 13.5 mg once daily (QD) on...
Energy level diagram and charge transfer mechanism of WN/CN- x plasmonic photocatalysts.
9106 Background: ASK120067 (Limertinib) is a newly developed third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitizing EGFR and T790M mutations. This study aimed to evaluate the efficacy safety of in patients with locally advanced or metastatic mutated non-small cell lung cancer (NSCLC). Methods: was single-arm, open-label, phase 2b conducted at 62 hospitals across China. Patients NSCLC centrally confirmed mutations tumor tissue blood...
Abstract Background Breast cancer is the most frequently diagnosed and 5th common cause of cancer-related death in Chinese women with over 416,000 new cases 117,000 deaths estimated 2020. Triple-negative breast (TNBC) represents 10%-20% cancer. Sacituzumab govitecan (SG) a Trop-2-directed antibody-drug conjugate approved for second-line or later (2L+) treatment metastatic (m)TNBC multiple countries, including US China. In pivotal phase 3 study ASCENT, which enrolled predominantly non-Asian...
<h3>Background</h3> IBI363 was designed to simultaneously block the PD-1/PD-L1 pathway and activate IL-2 with improved efficacy reduced toxicity. In previously reported phase 1 results, well tolerated promising in advanced melanoma. Herein, we present analysis of IO-naïve melanoma patients (defined as no previous exposure immune checkpoint inhibitors) from study (NCT05460767) an additional cohort a 2 (NCT06081920). <h3>Methods</h3> Eligible unresectable locally or metastatic were enrolled....
<h3>Background</h3> CCR8 is an important chemokine receptor expressed on intratumoral regulatory T cell (Tregs). Selective depletion of Tregs by targeting may be a promising therapeutic approach. QLP 2117 highly selective IgG1 antibody against with enhanced antibody-dependent cell-mediated cytotoxicity glycoengineering. Here we present the results ongoing phase 1a trial QLP2117 in advanced solid tumors. <h3>Methods</h3> The 1 recruited patients locally advanced, recurrent or metastatic...
Abstract Background: MET gene amplification is associated with poor prognosis in gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ). Savolitinib a potent highly selective oral tyrosine-kinase inhibitor. Here we reported the preliminary efficacy safety from phase 2 trial of savolitinib monotherapy patients (pts) MET-amplified advanced or metastatic GC/GEJ. (NCT04923932). Methods: Eligible pts had 2L+ GEJ GC, measurable lesions. Pts received at 600 mg QD for body weight...